Abstract
The global COVID-19 pandemic has resulted in unprecedented economic disruption, contracting the global economy by an estimated 3.5% in 2020. While the costs of the pandemic are well-documented, there is a lack of tools to measure the positive socio-economic impact of specific technological interventions. This paper presents COVIDCalc, a novel framework designed to quantify the Return on Investment (ROI) of AI-driven pre-screening tools. By utilizing a customizable ledger approach, COVIDCalc allows policymakers to estimate how marginal improvements in early detection—such as those provided by acoustic-based AI—can generate billions in value across healthcare, education, and the broader economy.
Introduction: The Economic Toll of COVID-19
The pandemic's impact spans far beyond direct healthcare costs, affecting labor markets, national inflation, and educational systems. Traditional analytical tools often focus on measuring these losses in isolation. For instance, the divergence between standard Consumer Price Index (CPI) and COVID-influenced inflation metrics highlights the systemic economic shifts triggered by the crisis.
To justify the deployment of AI-based pre-screening solutions, such as those analyzing cough acoustics via smartphones, a standardized method for calculating "value creation" is required. COVIDCalc addresses this gap by shifting the perspective from total loss to the potential gains achieved through early mitigation.
Methodology: The COVIDCalc Framework
COVIDCalc is a "working model" calculator that synthesizes data from established economic indicators, including the APIC infection cost model and the St. Louis Fed’s inflation trackers. The framework employs a classic Debit/Credit ledger approach:
- Debits: Represents the total cost of ownership (TCO) to bring an AI solution to market, including R&D, regulatory compliance, and deployment.
- Credits (Value Creation): Quantifies the positive outcomes, such as reductions in healthcare expenses, GDP preservation, lives saved, and decreased costs for PCR testing and educational disruptions.
The model is highly customizable, allowing users to input state-specific or national data and adjust assumptions regarding the degree of positive change (e.g., a conservative 0.1% improvement) attributed to the AI intervention.
Data Sources for AI Pre-Screening
While the focus of this work is the economic calculator, its utility is predicated on the feasibility of AI-driven screening. The authors cite several key datasets used to train and validate respiratory sound analysis models (SVMs, LSTMs, and Random Forests):
- Coswara & Virufy: Large-scale datasets of respiratory sounds and clinical cough samples.
- Sarcos: The SARS COVID-19 South Africa dataset.
- Institutional Datasets: Collections from the University of Cambridge, MIT, and the University of Lleida.
Results: Quantifying the Multiplier Effect
To demonstrate the calculator's utility, the paper provides a sample calculation based on a hypothetical $75 million investment to deploy an AI screening solution in the U.S. market. Even with conservative assumptions of a 0.1% to 1% positive impact, the model projects significant returns:
- Healthcare Savings: ~$60 million (0.1% reduction in COVID-related expenses).
- GDP Impact: ~$840 million (0.1% increase in GDP due to improved labor retention).
- Education & Testing: ~$58 million in combined savings from reduced PCR needs and school-related expense mitigation.
The total estimated positive benefit reaches $883 million, representing a net socio-economic value that far outweighs the initial R&D investment.
Discussion and Limitations
The primary strength of COVIDCalc is its ability to demonstrate how marginal improvements in screening can have massive downstream effects. However, the model's outputs are highly dependent on user assumptions. If the real-world efficacy of the AI tool falls below the assumed threshold, the ROI projections shift significantly.
Future work will focus on validating these economic projections against real-world deployment data and adapting the model for global contexts, particularly for low- and middle-income countries where low-cost acoustic biomarkers could provide the highest relative impact.
Summary updated